Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes

Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies.1–4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic therapy (PDT), but the treatment comes at a cost.5 The current goal of anti-vascular endothelial growth factor (VEGF) agents is to stabilise and/or improve vision. The natural history of untreated disease leads to irreversible visual loss in majority of patients.6 Current evidence-based literature is lacking for patients with “active, symptomatic” neovascular AMD with centre involvement and visual acuity better than 6/12 (20/40) at presentation. We present 12-month outcomes for neovascular AMD patients treated with Lucentis and presenting baseline visual acuity better than (6/12). Fourteen eyes of 14 patients with neovascular AMD were …